MyJournals Home  

RSS FeedsLMO2 as a Biomarker for Hypersensitivity to Genotoxic Therapy (Cancer Cell)

 
 

16 september 2019 17:01:47

 
LMO2 as a Biomarker for Hypersensitivity to Genotoxic Therapy (Cancer Cell)
 


In this issue of Cancer Cell, Parvin and colleagues identify the expression of LMO2 as a biomarker for DNA repair defects in lymphomas. Using isogenic cell lines and xenografts, the authors show that expression of LMO2 predicts sensitivity to PARP inhibition, especially in combination with genotoxic therapy.


 
198 viewsCategory: Cell Biology, Oncology
 
The Sly Oncogene: FOXA1 Mutations in Prostate Cancer (Cancer Cell)
Colon Cancer: Epithelial Notch Signaling Recruits Neutrophils to Drive Metastasis (Cancer Cell)
 
 
blog comments powered by Disqus


MyJournals.org
The latest issues of all your favorite science journals on one page

Username:
Password:

Register | Retrieve

Search:

Oncology


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten